Home > Boards > US OTC > Miscellaneous >

Rich Pharmaceuticals Inc. (RCHA)

Add RCHA Price Alert      Hide Sticky   Hide Intro
Moderator: Axeman
Search This Board:
Last Post: 8/26/2016 12:36:23 PM - Followers: 183 - Board type: Free - Posts Today: 0

RCHA Patent for Treatment of Hodgkin’s Lymphoma

Under terms of the agreement, Rich Pharmaceuticals, Inc. will obtain complete ownership and all interest in the indication, patents and intellectual property related to treatment of Hodgkin’s Lymphoma,
RCHA Recent News

Rich Pharmaceuticals Announces Additional Submission To The U.S. Food and Drug Administration (FDA)

BEVERLY HILLS, Calif., Nov. 23, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTCPK: RCHA) ("Rich"), with the advice and guidance of Theradex Systems, Inc.,

Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug
(IND) Application For The Treatment of Acute Myelocytic Leukemia

BEVERLY HILLS, Calif., Feb. 4, 2015 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (RCHA) ("Rich" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies in oncology, announced today that it has competed a GMP clinical batch of RP-323 study drug that was manufactured at the state-of-the-art Wuxi Apptec Biopharmaceutical's facility based in Shanghai, China.  This new batch of RP-323 represents a new second-generation compound with improved product usability and stability.  Rich Pharmaceuticals developed the new formulation and all regulatory required testing methods in 2014 and transferred the proprietary technology successfully to Wuxi Apptec for the GMP production of RP-323.  Currently, the new study drug is in the final examination stage at Wuxi Apptec and is expected to be shipped to clinical sites starting mid-February 2015 for the upcoming planned clinical trials.   
Rich Pharmaceuticals submitted its Investigational New Drug (IND) Application for a Phase 2 multi-center study to evaluate the safety and efficacy of RP-323 in patients with AML and MDS in October 2014. 
In connection with the IND, Rich Pharmaceuticals was required to manufacture sufficient quantities of RP-323 under GMP.
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer. 
Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec. 
We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."
About Rich Pharmaceuticals:
Rich Pharmaceuticals, Inc. (RCHA) is a biopharmaceutical company developing a treatment for Acute Myelocytic Leukemia (AML)/white blood cell elevation, Hodgkin's Lymphoma and other blood related diseases. 
Rich Pharmaceuticals' goal is to extend refractory patients life expectancy and increase quality of life. 
Rich Pharmaceuticals' primary development stage product candidate, RP-323, is being designed to treat blood and cancer related diseases through non-evasive outpatient facilities. 

Find out more at
WuXi PharmaTech, Inc. trades on the NYSE in the area of $40.00 per share under the ticker of WX with a $2.8 Billion Market Cap:

Below is the indicated Product Pipeline for RCHA:

Here is a key piece from the news as to how it applies:
"We believe RP-323 has best-in-class potential and holds significant promise for patients suffering from AML and MDS," said Ben Chang, Rich Pharmaceuticals' Chief Executive Officer.  Mr. Chang further stated, "We are especially excited to have a partner in the manufacture of RP-323 of the high caliber of Wuxi Apptec.  We expect to pursue the approval of the IND promptly and to be in clinical studies in the very near term."

Courtesy of Sibware: 
RCHA RP-323:Potential Market=$1 to 2 Billion/Year US.$5 Billion Worldwide. 

Business Overview 

The Company is developing RP-323 (formerly called PD-616) for the treatment of Acute Myelogenous Leukemia (AML), and to cause elevation of white blood cells
(WBC) in patients depleted of these elements due to various conditions.

Clinical Studies in Acute Myelocytic Leukemia 

Based on the known properties of RP-323, it was first administered in a pilot study in China, either alone or in combination with standard drugs and caused temporary remission of AML in some patients’ refractory to standard therapy. Several patients recovered sufficiently with RP-323 treatment to return to their normal occupations, symptom-free. 
Interest in these findings led to a Phase I investigator-sponsored trial in 35 patients by a leading oncologist at a leading cancer hospital in New Jersey, the University of Medicine and Dentistry of New Jersey (UMDNJ). 

Market Opportunities 


It is estimated that 40,000 people in the US have AML and an additional 14,000 are diagnosed annually with a yearly death rate of over 10,000.
Based on this incidence,
the potential market for RP-323 for the treatment of AML is approximately $1 to 2 billion peak sales annually in the US and more than $5 billion worldwide.

RCHA Key DD Posts:
Key RCHA & WX:NYSE Relationship
Respectfully, again, key with the Authorized Shares



Contact Us
9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

P: 424.230.7001
F: 424.230.7003




Monthly View

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#11359  Sticky Note This is a Share Printing Scam Stock... AVOID makinezmoney 03/11/16 02:37:25 PM
#11806   TIME FOR BEN TO REVERSE SPLIT AGAIN!!! onthegreen 08/26/16 12:36:23 PM
#11805   That is true but the CEOs don't help Axeman 08/25/16 08:11:58 PM
#11804   Pink sector is Naked Shorted to death by stoprun 08/25/16 08:09:42 PM
#11803   Boring you know it and I know it Axeman 08/25/16 04:52:50 PM
#11802   I do believe that is the same thing stoprun 08/25/16 04:48:45 PM
#11801   Go read all the filings and get a Axeman 08/25/16 04:21:21 PM
#11800   Link Please, sound familiar, as in GN-P!!!!!!!!!!!!!!! stoprun 08/25/16 04:19:36 PM
#11799   Impossible to say since we are in limbo Axeman 08/25/16 01:35:58 PM
#11798   This seems to be the census, before the otclad 08/25/16 01:29:35 PM
#11797   All I'm trying to do here is get stockscheers 08/25/16 04:40:40 AM
#11796   You need a lot more than news here Axeman 08/24/16 02:17:45 AM
#11795   Iam waiting for news too, but not sure josemaria 08/23/16 02:41:42 PM
#11794   Bring on the good news!!! Rich540 08/23/16 04:11:33 AM
#11793   the moving average is keeping it's strength which stockscheers 08/23/16 03:34:39 AM
#11792   Either way this RCHA is a toxic disaster. Axeman 08/19/16 01:17:32 PM
#11791   I see, it only matters when the price stoprun 08/19/16 01:11:25 PM
#11790   Doesn't matter this Ben show is a failure Axeman 08/18/16 10:40:15 PM
#11789   And how much was the last trade that stoprun 08/18/16 10:25:24 PM
#11788   LOL! CHINESE SHARE SELLING SCAM!!! onthegreen 08/18/16 10:10:11 PM
#11787   How is he stuck?? Rich540 08/18/16 08:45:11 PM
#11786   It is too bad that Ben is in Axeman 08/18/16 03:30:34 PM
#11785   Yeap, is was up 233% for just a josemaria 08/18/16 03:28:10 PM
#11784   Now down 33%. Diluter/Ben must have Axeman 08/18/16 03:25:15 PM
#11783   Wow. up 200% ! josemaria 08/18/16 12:40:25 PM
#11782   I have to agree with you on this otclad 08/17/16 08:04:44 PM
#11781   HAHHAA Apparently he is not concerned about all otclad 08/17/16 08:01:49 PM
#11780   Umm how can he state he expects to king koopa 08/17/16 06:20:35 PM
#11779   Just wondering what effect is the R/S going stockscheers 08/17/16 05:10:25 AM
#11778   As expected after the RS down she comes... otclad 08/16/16 03:24:58 PM
#11777   Time for another Reverse Split!!! onthegreen 08/15/16 11:38:26 PM
#11776   LOL, Chinese Share Selling Scam onthegreen 08/02/16 02:09:10 PM
#11775   let's see how it hold up the next stockscheers 08/02/16 04:25:23 AM
#11774   Ben has nothing going on with trials getting Axeman 08/01/16 01:01:44 PM
#11773   Can transition happens soon? stockscheers 07/29/16 05:05:28 AM
#11772   Ben loves to R/S! That way he can onthegreen 07/27/16 03:14:44 PM
#11771   R/S is never a good idea. stockscheers 07/27/16 02:19:35 AM
#11770   Ben will R/S this again soon. onthegreen 07/26/16 09:57:07 PM
#11769   Ask stacked at 30 million now ar .0004. Ben Axeman 07/13/16 11:41:23 AM
#11768   A more good strategy on the business is stockscheers 07/13/16 02:34:24 AM
#11767   Down....Down. Nothing new on the news front imo Axeman 07/11/16 01:06:03 PM
#11766   Watching this for market direction. stockscheers 07/11/16 04:59:15 AM
#11765   LOL $7 paint trade with 10 million on onthegreen 07/08/16 03:33:27 PM
#11764   More 8k's on the way!!! onthegreen 07/08/16 01:37:15 PM
#11763   Look at the past and tell me otherwise Axeman 07/08/16 11:40:56 AM
#11762   How do you know that "Conversions will NEVER stoprun 07/08/16 11:38:44 AM
#11761   Unfortunately Ben has continued to destroy value with Axeman 07/08/16 11:23:52 AM
#11760   hopefully breakout of the consolidation range for real. stockscheers 07/07/16 04:56:43 AM
#11759   Ben will Reverse it again after he dumps onthegreen 07/05/16 08:49:00 AM
#11758   What's the worst that could happen here? stockscheers 07/05/16 05:01:10 AM
#11757   RCHA = CHINESE SHARE SELLING SCAM. THAT IS onthegreen 07/01/16 04:51:51 PM